DDInter837 DDInter922
Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®.
Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD).[A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD. Compared to the anti-CD20 antibody [rituximab], which is also used to treat NMOSD, inebilizumab has broader specificity.[A214280, A214289, A214292, A214295, A214298, A214301] Inebilizumab was granted FDA approval on June 11, 2020, for the treatment of anti-aquaporin 4 positive NMOSD patients. Given its mechanism of action and good safety profile, it may prove useful in the treatment of other conditions linked to autoimmune antibody production or B-cell malignancies.[A214280, A214295] On January 16, 2024, Iinebilizumab also received Health Canada approval for the same indication.
Golimumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Golimumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Golimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Golimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diiodohydroxyquinoline
Golimumab {u} may lead to a major life threatening interaction when taken with {v} Cyclophosphamide
Golimumab {u} may lead to a major life threatening interaction when taken with {v} Avapritinib
Golimumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Golimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Golimumab may lead to a major life threatening interaction when taken with Cyclophosphamide
Golimumab may lead to a major life threatening interaction when taken with Avapritinib